In conclusion, our studies demonstrate that stress protein TRB3 mediates metabolic factors including insulin/IGF-induced tumour development and progression; this work provides the proof-of-concepts for targeting the TRB3/p62 interaction as a therapeutic strategy against cancers, particularly in T2D patients with cancers. Here, INS is linked to type 2 diabetes mellitus.